Romanian Society of Pharmaceutical Sciences

« Back to Farmacia Journal 4/2015

ANALYSIS OF MARKET DATA REGARDING THE MEDICINES USED IN TREATMENT OF DYSLIPIDAEMIA

CORNELIA REVNIC1, REMUS CÂMPEAN1, ANAMARIA BOBOIA2*

"Iuliu Haţieganu” University of Medicine and Pharmacy Cluj-Napoca, Faculty of Pharmacy
1.Mathematical and Computer Science Department, 6 Pasteur, 400349, Cluj-Napoca, Romania
2.Pharmaceutical Management, Marketing and Legislation Department, 8 Victor Babeş, 400012, Cluj-Napoca, Romania

Download Full Article PDF

Dyslipidaemias are some of the most frequent metabolic diseases encountered in medical practice. Due to the increasing number of patients suffering from dyslipidaemia, its treatment is frequently on medical prescriptions presented to pharmacies. It was analysed a volume of 360 of patients and THEIR medical prescriptions provided by 12 pharmacies from Cluj-Napoca during the year 2010. The drugs most frequently prescribed in the treatment of some forms of dyslipidaemia have been the following: Simvastatin®10, Simvastatin®20, Simvastatin®40, Rosuvastatin®5, Rosuvastatin®10, Rosuvastatin®20, Atorvastatin®10, Atorvastatin®20, Atorvastatin®40, Fenofibrat®160, Omacor®. All patients considered, who has been administered one of these drugs, were chosen so that to respect the homogeneity on each age category, namely, the age’s interval is quite symmetrically comparing to the average age. The aim of this paper was to find the most frequently prescribed drug for dyslipidaemia. Also, the median differences between the younger and older groups were tested for statistical significance using the Mann-Whitney test. In order to test the effect of medical treatment on 12 subgroups corresponding to the period of time studied, namely, on 12 months, a Kruskal-Wallis nonparametric test was used.